Evidence map›Paper›PMID 40375363›Full record

ArticleRedox report : communications in free radical research2025

Therapeutic combination of L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate in Friedreich's ataxia: insights from in vitro models.

Fred Jonathan Edzeamey, Zenouska Ramchunder, Adamo Valle Gómez, Haobo Ge, Carlo Marya Thomas Marobbio, Charareh Pourzand, Sara Anjomani Virmouni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox report : communications in free radical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fred Jonathan EdzeameyDivision of Biosciences, College of Health, Medicine, and Life Sciences (CHMLS), Institute of Environment, Health & Societies, Brunel University London, London, UK.
Zenouska RamchunderDivision of Biosciences, College of Health, Medicine, and Life Sciences (CHMLS), Institute of Environment, Health & Societies, Brunel University London, London, UK.
Adamo Valle GómezEnergy Metabolism and Nutrition, Research Institute of Health Sciences (IUNICS), University of Balearic Islands, Palma, Spain.
Haobo GeDepartment of Life Sciences, University of Bath, Bath, UK.
Carlo Marya Thomas MarobbioDepartment of Bioscience, Biotechnology and Environment, University of Bari, Bari, Italy.
Charareh PourzandDepartment of Life Sciences, University of Bath, Bath, UK.
Sara Anjomani VirmouniDivision of Biosciences, College of Health, Medicine, and Life Sciences (CHMLS), Institute of Environment, Health & Societies, Brunel University London, London, UK.ORCID 0000-0001-5831-780X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Friedreich's Ataxia (FRDA) is a rare neurological disorder caused by an abnormal expansion of Guanine-Adenine-Adenine (GAA) repeat in intron 1 of the

Indexed as

AcetylcysteineAscorbic AcidDimethyl FumarateFriedreich AtaxiaAntioxidantsCell SurvivalFibroblastsFrataxinHumansIron-Binding ProteinsMembrane Potential, MitochondrialMitochondriaNF-E2-Related Factor 2Oxidative StressReactive Oxygen SpeciesAcetylcysteineAntioxidantsAscorbic AcidDimethyl FumarateFrataxinIron-Binding ProteinsNF-E2-Related Factor 2Reactive Oxygen SpeciesantioxidantsfrataxinFRDAFriedreich’s ataxiamitochondrial dysfunctionneurodegenerationoxidative stressreactive oxygen species

Identifiers

PMID40375363
PMCPMC12082744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.